Rayaldee
Total Payments
$3.9M
Transactions
19,730
Doctors
4,067
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $172,309 | 7,287 | 2,353 |
| 2018 | $3.6M | 6,964 | 2,312 |
| 2017 | $191,149 | 5,479 | 2,396 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 36 | 84.1% |
| Food and Beverage | $372,518 | 19,582 | 9.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $212,677 | 62 | 5.4% |
| Travel and Lodging | $14,207 | 31 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $14,193 | 13 | 0.4% |
| Consulting Fee | $13,685 | 4 | 0.3% |
| Gift | $9.90 | 2 | 0.0% |
Payments by Type
Research
$3.3M
36 transactions
General
$627,289
19,694 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Repeated-dose Safety, Efficacy, PK and PD of CTAP101, IR Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With SHPT, CKD 3-4 and VDI | OPKO Pharmaceuticals, LLC | $3.2M | 0 |
| CTAP101?CL?2010 | OPKO Pharmaceuticals, LLC | $24,200 | 0 |
| CTAP101-CL-3003 | OPKO Ireland Global Holdings, Ltd. | $16,800 | 0 |
| CTAP101-CL-1017 | OPKO Ireland Global Holdings, Ltd. | $12,321 | 0 |
| CTAP101_CL_2010 | OPKO Pharmaceuticals, LLC | $8,950 | 0 |
Top Doctors Receiving Payments for Rayaldee
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $3.3M | 50 |
| , DO | Critical Care Medicine | Hinsdale, IL | $18,753 | 36 |
| , MD | Nephrology | Springfield, MA | $16,630 | 22 |
| , MD | Nephrology | Denver, CO | $15,689 | 10 |
| , M.D | Internal Medicine | San Antonio, TX | $11,934 | 71 |
| , DO | Nephrology | Chicago, IL | $11,706 | 9 |
| , MD, PHD | Internal Medicine | Meridian, ID | $11,419 | 23 |
| Jill Lindberg | — | Metairie, LA | $8,967 | 13 |
| , M.D | Nephrology | New York, NY | $8,897 | 7 |
| , M.D | Nephrology | Houston, TX | $7,665 | 25 |
| , MD | Nephrology | Indianapolis, IN | $6,145 | 7 |
| , M.D | Nephrology | Poland, OH | $5,890 | 23 |
| , M.D | Internal Medicine | Houston, TX | $5,814 | 2 |
| , M.D | Nephrology | Greenville, NC | $5,763 | 14 |
| , M.D | Nephrology | Houston, TX | $5,389 | 37 |
| , MD | Nephrology | Eatontown, NJ | $5,309 | 10 |
| , MD | Nephrology | Hershey, PA | $5,244 | 1 |
| , MD | Family Medicine | Chambersburg, PA | $4,966 | 27 |
| , M.D | Nephrology | La Mesa, CA | $4,931 | 11 |
| , M.D | Internal Medicine | Houston, TX | $4,899 | 22 |
| , M.D | Nephrology | Chicago, IL | $4,729 | 8 |
| , M.D | Nephrology | Gurnee, IL | $4,573 | 9 |
| , M.D | Nephrology | Terre Haute, IN | $4,521 | 7 |
| , M.D | Nephrology | Falls Church, VA | $4,504 | 5 |
| , MD | Nephrology | South Bend, IN | $4,502 | 10 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.9M
- Total Doctors 4,067
- Transactions 19,730
About Rayaldee
Rayaldee is a drug associated with $3.9M in payments to 4,067 healthcare providers, recorded across 19,730 transactions in the CMS Open Payments database. The primary manufacturer is OPKO Pharmaceuticals, LLC.
Payment data is available from 2017 to 2019. In 2019, $172,309 was paid across 7,287 transactions to 2,353 doctors.
The most common payment nature for Rayaldee is "Unspecified" ($3.3M, 84.1% of total).
Rayaldee is associated with 5 research studies, including "Repeated-dose Safety, Efficacy, PK and PD of CTAP101, IR Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With SHPT, CKD 3-4 and VDI" ($3.2M).